StockResearch Intelligence Weekly #27

1. Opening

Big Tech put up the numbers. The rest of the AI trade got caught bluffing. From the July 24 close through Friday, July 31, the S&P 500 gained 1.05% to 7,489.72. The Nasdaq Composite rose 1.59% to 25,373.85. The Dow added 1.04% to 52,485.03. The Russell 2000 did basically nothing, up 0.05% at 2,931.34. AP has the same closes and changes.

Under those green index numbers, the tape split in half. IGV rose 7.50% and XLY gained 6.11% as Microsoft, Amazon, Oracle, Salesforce, and Alphabet ripped higher. SOXX fell 4.20%. Micron, Qualcomm, KLA, AMD, and Vertiv got hit anyway. Microsoft gained 21.75% and Amazon gained 17.00%. Vertiv fell 16.80%. KLA lost 13.16%. Same AI story, very different bill.

Here is the point. AI is not dead. Lazy AI exposure is. Amazon rallied after profit more than tripled and AWS accelerated. Microsoft had its best day in nearly 18 years. Chip suppliers were left explaining memory prices, input costs, customer concentration, and valuations that already assumed the good news. The market wanted receipts.

Key themes

• Proof beat slogans. Revenue, profit, cash flow. Anything less got ignored.
• Software got paid. Semiconductors got another reminder that a giant addressable market does not fix a bad entry price.
• This was not a clean lower-rate rally. TLT and utilities fell. The easy macro story does not work.
• A huge target gap is bait unless the business can back it up. We want the reset and the proof.

2. Strengths

• The market finally charged rent for using the letters AI. Microsoft rose 21.75%, Amazon gained 17.00%, Oracle advanced 12.94%, Salesforce climbed 12.44%, and Alphabet added 11.38%. IGV gained 7.50%. Good. Companies that showed demand got paid. Suppliers priced for perfection did not. The rally was still narrow though. A few enormous earnings moves carried the index while the Russell 2000 sat there like dead office furniture.
• Execution beat labels. Intuitive Surgical gained 4.69% after its reset. Q2 revenue rose 19% to $2.89 billion, procedures increased 16%, and GAAP net income reached $818 million. T-Mobile fell 4.10%, but service revenue rose 9% to $19.0 billion and adjusted free cash flow reached $4.8 billion. One chart went up, one went down. The businesses still did the work.
• The boring valuation calls beat the speculative stuff. Uber gained 6.70% after we flagged a 55.3% price-to-consensus gap and strong free cash flow. Newmont stayed positive while GLD slipped 0.10%. Corning fell 5.73%, which is why we refused to turn a bullish model signal into a pre-earnings BUY. QXO was the miss. One week proves nothing, sure. It still tells us where the bad sizing would have hurt.

3. Weaknesses

• Semiconductors failed. SOXX fell 4.20%. Qualcomm lost 11.59%, Micron fell 10.63%, AMD dropped 8.77%, and KLA lost 13.16%. Qualcomm fiscal Q3 revenue fell 4% to $9.95 billion and handset revenue fell 20%. Automotive rose 61%, but the smaller business did not rescue the quarter. Cheap can mean opportunity. It can also mean estimates are still wrong.
• The index looked better than the market. Russell 2000 gained 0.05%. Utilities fell 4.19%, industrials lost 1.54%, materials declined 1.62%, real estate fell 1.92%, and TLT lost 1.20%. That is not a broad risk-on. It is a concentrated earnings rally. Fine while the winners keep delivering. Nasty the minute one of them misses.
• The low-cap target gaps look ridiculous. Mirion sits 72.2% below its mean target, Zillow 98.9% below, Summit Therapeutics 99.7% below. So what. Mirion has acquisitions to integrate. Zillow reports after a 10.73% rebound. Summit is pre-revenue and burning cash through a clinical program. Consensus starts the screen. It does not finish the job.

4. Weekly Market Recap

Call it what it was. Microsoft, Amazon, Salesforce, and Alphabet showed the money and rallied. Apple, Qualcomm, Micron, and Vertiv gave investors costs, weak spots, or too much valuation and got sold. The indexes closed higher. Russell 2000 went nowhere. SOXX fell. Capital was available, just not for every company wearing an AI badge.

5. Top 3 Stock Picks for Long-Term Investment

1. Intuitive Surgical (ISRG) – BUY

$353.33 | $124.82B market cap | 32.7x FY2026 consensus EPS | 50-day / 200-day: $399.39 / $481.88 | Mean target: $491.15 | Target gap: +39.0%

• Thesis. Intuitive Surgical got cheaper while the business kept working. Q2 revenue rose 19% to $2.89 billion. Worldwide procedures increased 16%, da Vinci procedures rose 15%, and Ion procedures jumped 36%. The company placed 468 da Vinci systems, including 246 da Vinci 5 systems. Installed base reached 11,710 da Vinci systems and 1,096 Ion systems. GAAP net income was $818 million, or $2.29 per diluted share. Real machines, real procedures, real profit.
• The ugly bit. Management expects 2026 procedure growth of 13.5%-15.5% and gross margin of 68%-69%, with tariffs taking about one percentage point. The stock is below its $399.39 50-day average and $481.88 200-day average. At 32.7x FY2026 consensus EPS, it is still expensive. Just less stupidly expensive than before.
• Why now. The $353.33 close is 39.0% below the $491.15 mean target and a little below the published $357.44 low target. Better entry. The installed base also keeps feeding instruments, accessories, service, and training revenue. Hospitals do not need to replace every machine tomorrow. They need to keep using them.
• Do not call this a value stock. It is not. The case is simpler. We can buy a profitable category leader with measurable procedure growth at a price that no longer demands absolute perfection. The recovery may be messy.
• Forecast model check. One day says UP 0.35% to $354.57 at 51.23% confidence for August 3. Three days says DOWN 0.02% to $353.25 at 59.76% for August 5. Seven days says UP 1.30% to $357.92 at 66.85% for August 11. Mixed, low conviction, barely useful for timing. We rate ISRG a BUY because the business and the reset matter more than three weak model shrugs.
• Risk and verdict. Procedure growth can slow. Hospital budgets can tighten. Tariffs, costs, competition, and a premium multiple can all hurt. Those are real risks, not decorative footnotes.
• BUY: accumulate, do not lunge. The $399.39 50-day average is the first recovery level, then the $481.88 200-day average. The $491.15 mean target is a reference.

2. T-Mobile US (TMUS) – BUY ON WEAKNESS

$172.71 | $185.26B market cap | 15.9x FY2026 consensus EPS | 50-day / 200-day: $183.58 / $199.07 | Mean target: $235.50 | Target gap: +36.4%

• Thesis. T-Mobile is a cash machine with an ugly chart. Q2 service revenue rose 9% to $19.0 billion. Postpaid service revenue increased 13% to $15.9 billion. Net income was $3.2 billion and diluted EPS was $2.99. Core adjusted EBITDA reached $9.5 billion, up 12%. Adjusted free cash flow hit $4.8 billion, up 4%. Merger costs were there. Cash showed up anyway.
• The stock closed at $172.71 after falling 4.10% for the week. It sits below the $183.58 50-day average and $199.07 200-day average, barely above the $169.68 weekly low. Mean target is $235.50, a 36.4% gap. At about 15.9x FY2026 consensus EPS, the price is reasonable for recurring revenue and billions in cash flow. Not cheap trash. A reset.
• Why now. T-Mobile gets us away from the same AI capex trade everyone already owns. No dramatic product launch needed. Service revenue, network quality, customer economics, integration, capital returns. The chart is weak, so buy in pieces. Throwing the whole position at one red candle is not conviction. It is impatience.
• The stock looks worse than the business. That is the trade. Revenue quality and cash generation are visible while the shares sit near the weekly low and under both trend lines. It can stay weak. We are buying the cash engine, not pretending the chart already turned.
• Forecast model check. One day says DOWN 0.08% to $172.57 at 62.40% confidence for August 3. Three days says DOWN 0.04% to $172.64 at 64.29% for August 5. Seven days says DOWN 0.75% to $171.42 at 63.24% for August 11. We disagree long term. We listen short term. Every reading is below 70%, so this is a timing warning, not a veto.
• Risk and verdict. Competition, promotions, integration, network spending, churn, regulation, financing. Plenty can go wrong.
• BUY ON WEAKNESS: add gradually around this range. $183.58 and $199.07 are the first recovery levels. $235.50 is the medium-term consensus reference. The bearish model lean is exactly why we are not chasing.

3. Qualcomm (QCOM) – HOLD

$147.61 | $154.99B market cap | 13.9x FY2026 consensus EPS | 50-day / 200-day: $198.51 / $169.01 | Mean target: $204.05 | Target gap: +38.2%

• Thesis. Qualcomm is cheap because the quarter was bad. Fiscal Q3 revenue was $9.95 billion, down 4%. GAAP net income fell 25% to $2.00 billion. GAAP EPS fell 23% to $1.87 and non-GAAP EPS fell 20% to $2.21. Handset revenue dropped 20% to $5.09 billion. Automotive rose 61% to $1.59 billion and IoT grew 9% to $1.83 billion. Diversification is real. It is also too small to save the whole result yet.
• Management guided fiscal Q4 revenue to $9.7-$10.5 billion and non-GAAP EPS to $2.05-$2.25. Input costs are rising across wafers, assembly, testing, advanced packaging, memory, basically the whole kitchen. Pricing may recover some of it later. Later does not protect today’s margin. A 13.9x FY2026 P/E and 38.2% target gap are not enough for a BUY.
• Why hold. The franchise is not broken. Qualcomm returned $2.3 billion to shareholders, including $1.4 billion of repurchases and $973 million of dividends. Automotive and IoT are growing. Management expects non-handset revenue, including data center, to accelerate in fiscal 2027. The stock is below its $169.01 200-day average and $198.51 50-day average. A lot of disappointment is already sitting in the price.
• What is missing. Proof that diversification can change total earnings before handset weakness eats the benefit. Automotive growth looks great because the base is smaller. Pricing takes time. That is why the multiple is low and the target gap is wide. QCOM can become a BUY. It has not earned it yet.
• Forecast model check. One day says UP 0.07% to $147.72 at 58.74% confidence for August 3. Three days says UP 0.02% to $147.64 at 54.01% for August 5. Seven days says UP 0.14% to $147.82 at 69.05% for August 11. Those moves are pocket lint. The model hints at stabilization. It does not say estimates bottomed.
• Risk and verdict. Handsets, customer vertical integration, China, suppliers, input costs, margin pressure. The list is not short.
• HOLD: existing investors can keep a measured position. New buyers should wait for handset stabilization or proof that automotive, IoT, and data center are closing the hole. Above $169.01 would improve the setup. $204.05 is consensus, not destiny.

6. Low-Cap Opportunities

Low caps stay inside the $2-$15 billion market-cap box. Same price-versus-consensus screen, less room for nonsense.

1. Mirion Technologies (MIR) – SPECULATIVE BUY

$14.98 | $3.66B market cap | 27.7x FY2026 consensus EPS | 50-day / 200-day: $17.09 / $21.36 | Mean target: $25.80 | Target gap: +72.2%

• Thesis. Mirion sells radiation detection and monitoring gear into nuclear, medical, defense, and research markets. Q2 revenue rose 19.7% to $266.8 million. Adjusted EBITDA increased 27.5% to $65.3 million. Orders excluding Paragon and Certrec rose 10% to $229 million. Include the acquisitions and orders rose 40% to $291 million. GAAP net income was $8.1 million and adjusted EPS was $0.12. This is an operating business, not a glowing nuclear mood board.
• Management kept 2026 revenue growth at 22%-24%, organic growth at 5%-7%, adjusted EBITDA at $285-$300 million, and adjusted free cash flow at $155-$175 million. Good numbers. The catch is obvious. Acquisitions are doing part of the lifting, integration has to work, and the stock fell 9.43% for the week below both moving averages.
• Verdict. SPECULATIVE BUY: $14.98 is 72.2% below the $25.80 mean target and below the published $23 low target. Small position. No hero sizing. $17.09 is the first recovery level. Lose the $14.11 weekly low and the setup gets worse fast.
• Watch organic growth. Acquisitions can add scale and make the headline pretty while the old business drags its feet. Mirion needs to hit the organic range and turn it into cash. Until then, speculative means speculative.

2. Zillow Group (Z) – HOLD

$34.06 | $8.18B market cap | 14.9x FY2026 consensus EPS | 50-day / 200-day: $33.29 / $51.64 | Mean target: $67.75 | Target gap: +98.9% | Q2 results: Wednesday, August 5, 2026

• Thesis. Zillow’s last reported quarter was actually good. Q1 revenue rose 18% to $708 million. For Sale revenue rose 12%, Mortgages jumped 56%, and Rentals grew 42%. Net income improved to $46 million from $8 million. Operating cash flow was $200 million and adjusted free cash flow was $127 million.
• The stock gained 10.73% this week and closed above the $33.29 50-day average. It is still far below the $51.64 200-day average. Mean target is $67.75, a 98.9% gap. Big number. Bad timing. Zillow reports after the close Wednesday, August 5. Housing activity, mortgage rates, partner economics, guidance, all of it can move the stock hard.
• Verdict. HOLD: wait for the report. Buying after a double-digit weekly rebound right before earnings is how people turn a decent thesis into a bad entry. Confirm revenue, profit, and cash conversion first.

3. Summit Therapeutics (SMMT) – NO TRADE

$13.02 | $10.11B market cap | Pre-revenue | 50-day / 200-day: $14.77 / $17.05 | Mean target: $26.00 | Target gap: +99.7%

• Thesis. Summit is ivonescimab. That is the equity story. More than 4,000 patients have been treated in clinical studies and the Phase III program is broad. The FDA accepted the biologics license application in a defined non-small-cell lung-cancer setting and set November 14, 2026 as the PDUFA goal date. Updated HARMONi data showed a 0.76 overall-survival hazard ratio in western and Asian subgroups. Serious asset. Still one asset.
• The upside is large and the downside has a trapdoor. Summit had $690.7 million in cash, equivalents, and short-term investments at June 30. It used $263.4 million in operating cash during the first half. It raised $230.8 million through the ATM in Q2 and another $68.4 million afterward. Pre-revenue. Q2 net loss was $215.7 million. The $26 mean target does not pay the bills.
• Verdict. NO TRADE: wait. The stock is below both moving averages and barely above the $12.25 weekly low. FDA approval could launch it. A bad outcome could wreck it. A 99.7% target gap is not a margin of safety when the whole thing can gap through the floor.

7. Strategic Recap & Forward Outlook

This week punished autopilot. Microsoft and Amazon showed that AI spending can turn into cloud growth and earnings. Software recovered. Semiconductors, utilities, real estate, and small caps did not join the party. The indexes look broad from far away. Up close, a few companies carried the furniture.

We buy the resets with proof. Intuitive Surgical and T-Mobile. We hold Qualcomm because cheap hardware with falling handset revenue is still hardware with falling handset revenue. Mirion gets speculative sizing. Zillow waits for August 5. Summit gets no money. Binary science plus heavy cash burn is not courage, it is a coin flip wearing a lab coat.

A good company can be a bad purchase. A damaged chart can be a good entry. That is the whole job. Do not buy every dip. Buy the dips where cash, recurring demand, or confirmed growth survived the fall.

Forward Outlook

• Monday, August 3 – July ISM Manufacturing PMI lands at 10:00 a.m. ET. If software and consumer discretionary keep leading while yields rise, fine. If not, the rally was thinner than it looked.
• Tuesday, August 4 – June JOLTS arrives at 10:00 a.m. ET. Labor demand either cools cleanly or it does not. The market has already priced the friendly version.
• Wednesday, August 5 – July ISM Services PMI is out at 10:00 a.m. ET. Zillow reports after the close. That report decides whether our low-cap HOLD stays a HOLD. ISM release calendar
• Thursday, August 6 – Preliminary Q2 Productivity and Costs arrives at 8:30 a.m. ET with weekly jobless claims. Labor costs matter. Another soft macro fairy tale does not.
• Friday, August 7 – July Employment Situation at 8:30 a.m. ET. Payrolls, unemployment, wages, revisions. The market wants weak enough for rate relief and strong enough for earnings. Cute. BLS August schedule

Disclaimer: StockResearch Intelligence Weekly is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All data is sourced from third-party providers and believed accurate as of the publication date but is not guaranteed. Price targets and verdicts reflect the author’s analysis and may change without notice. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Conduct your own research and consult a licensed financial advisor before making investment decisions. The author may hold positions in securities mentioned.